File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antiviral therapy for respiratory tract infections

TitleAntiviral therapy for respiratory tract infections
Authors
KeywordsAntiviral
Nosocomial
Respiratory tract infection
Virus
Issue Date2008
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/RES
Citation
Respirology, 2008, v. 13 n. 7, p. 950-971 How to Cite?
AbstractViruses are important pathogens causing respiratory tract infections both in the community and health-care facility settings. They are extremely common causes of morbidity in the competent hosts and some are associated with significant mortality in the compromised individuals. With wider application of molecular techniques, novel viruses are being described and old viruses are found to have new significance in different epidemiological and clinical settings. Some of these emerging pathogens may have the potential to cause pandemics or global spread of a severe disease, as exemplified by severe acute respiratory syndrome and avian influenza. Antiviral therapy of viral respiratory infections is often unnecessary in the competent hosts because most of them are self-limiting and effective agents are not always available. In the immunocompromised individuals or for infections caused by highly pathogenic viruses, such as avian influenza viruses (AIV), antiviral treatment is highly desirable, despite the fact that many of the agents may not have undergone stringent clinical trials. In immunocompetent hosts, antiviral therapy can be stopped early because adaptive immune response can usually be mounted within 5-14 days. However, the duration of antiviral therapy in immunosuppressed hosts depends on clinical and radiological resolution, the degree and duration of immunosuppression, and therefore maintenance therapy is sometimes needed after the initial response. Immunotherapy and immunoprophylaxis appear to be promising directions for future research. Appropriate and targeted immunomodulation may play an important adjunctive role in some of these infections by limiting the extent of end-organ damage and multi-organ failure in some fulminant infections. © 2008 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/59415
ISSN
2023 Impact Factor: 6.6
2023 SCImago Journal Rankings: 1.559
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, SSYen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2010-05-31T03:49:38Z-
dc.date.available2010-05-31T03:49:38Z-
dc.date.issued2008en_HK
dc.identifier.citationRespirology, 2008, v. 13 n. 7, p. 950-971en_HK
dc.identifier.issn1323-7799en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59415-
dc.description.abstractViruses are important pathogens causing respiratory tract infections both in the community and health-care facility settings. They are extremely common causes of morbidity in the competent hosts and some are associated with significant mortality in the compromised individuals. With wider application of molecular techniques, novel viruses are being described and old viruses are found to have new significance in different epidemiological and clinical settings. Some of these emerging pathogens may have the potential to cause pandemics or global spread of a severe disease, as exemplified by severe acute respiratory syndrome and avian influenza. Antiviral therapy of viral respiratory infections is often unnecessary in the competent hosts because most of them are self-limiting and effective agents are not always available. In the immunocompromised individuals or for infections caused by highly pathogenic viruses, such as avian influenza viruses (AIV), antiviral treatment is highly desirable, despite the fact that many of the agents may not have undergone stringent clinical trials. In immunocompetent hosts, antiviral therapy can be stopped early because adaptive immune response can usually be mounted within 5-14 days. However, the duration of antiviral therapy in immunosuppressed hosts depends on clinical and radiological resolution, the degree and duration of immunosuppression, and therefore maintenance therapy is sometimes needed after the initial response. Immunotherapy and immunoprophylaxis appear to be promising directions for future research. Appropriate and targeted immunomodulation may play an important adjunctive role in some of these infections by limiting the extent of end-organ damage and multi-organ failure in some fulminant infections. © 2008 The Authors.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/RESen_HK
dc.relation.ispartofRespirologyen_HK
dc.subjectAntiviral-
dc.subjectNosocomial-
dc.subjectRespiratory tract infection-
dc.subjectVirus-
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshHumansen_HK
dc.subject.meshRespiratory Tract Infections - drug therapy - virologyen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleAntiviral therapy for respiratory tract infectionsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1323-7799&volume=13&issue=7&spage=950&epage=971&date=2008&atitle=Antiviral+therapy+for+respiratory+tract+infections.en_HK
dc.identifier.emailWong, SSY:samsonsy@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityWong, SSY=rp00395en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1843.2008.01404.xen_HK
dc.identifier.pmid18922142en_HK
dc.identifier.scopuseid_2-s2.0-54349104687en_HK
dc.identifier.hkuros167116en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-54349104687&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue7en_HK
dc.identifier.spage950en_HK
dc.identifier.epage971en_HK
dc.identifier.isiWOS:000260308300002-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridWong, SSY=13310021400en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.citeulike3450110-
dc.identifier.issnl1323-7799-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats